The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Current concepts and management of glioblastoma
Open accessAbstract
Glioblastoma is the most common malignant primary brain tumor in adults. Its often rapid clinical course, with many medical and psychosocial challenges, requires a multidisciplinary management. Modern multimodality treatment and care improve patients' life expectancy and quality of life. This review covers major aspects of care of glioblastoma patients with a focus on the management of common symptoms and complications. We aim to provide a guide for clinicians confronted with glioblastoma patients in their everyday practice. Ann Neurol 2011;
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationVerhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“Fluorescence-guided neurosurgery with 5aminolevulinic acid has been shown to enable more complete tumor resections, translating into improvement in the 6-month progression-free survival rates, but without increase in overall survival.(30) Intraoperative monitoring and cortical and subcortical stimulation reduce the ri…”
BackgroundBevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Distinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
Semenza, G. L. (2010) · Oncogene · doi:10.1038/onc.2009.441 · Cited by 1,712
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,394
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
Ohgaki, H., & Kleihues, P. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.6.479 · Cited by 1,381
Westphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Epidemiology and etiology of gliomas
Ohgaki, H., & Kleihues, P. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-0991-y · Cited by 1,252
Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells
Piccirillo, S. G. M., Reynolds, B. A., Zanetti, N., Lamorte, G., Binda, E., Broggi, G., Brem, H., Olivi, A., Dimeco, F., & Vescovi, A. L. (2006) · Nature · doi:10.1038/nature05349 · Cited by 1,176
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Roa, W., Brasher, P. M. A., Bauman, G., Anthes, M., Bruera, E., Chan, A., Fisher, B., Fulton, D., Gulavita, S., Hao, C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.082 · Cited by 904
Glantz, M. J., Cole, B. F., Forsyth, P. A., Recht, L. D., Wen, P. Y., Chamberlain, M. C., Grossman, S. A., & Cairncross, J. G. (2000) · Neurology · doi:10.1212/wnl.54.10.1886 · Cited by 858
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Self-citationRadiotherapy for Glioblastoma in the Elderly
Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., Guillamo, J.-S., Jadaud, E., Colin, P., Bondiau, P.-Y., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065901 · Cited by 792
Genome-wide association study identifies five susceptibility loci for glioma
Shete, S., Hosking, F. J., Robertson, L. B., Dobbins, S. E., Sanson, M., Malmer, B., Simon, M., Marie, Y., Boisselier, B., Delattre, J.-Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.407 · Cited by 788
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
Self-citationMurat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
Self-citationGalanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 575
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 550
Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L. M., Mason, W., Weller, M., Hong, S., Musib, L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 525
Self-citationAgnelli, G., Piovella, F., Buoncristiani, P., Severi, P., Pini, M., D'Angelo, A., Beltrametti, C., Damiani, M., Andrioli, G. C., Pugliese, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390204 · Cited by 523
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility
Wrensch, M., Jenkins, R. B., Chang, J. S., Yeh, R.-F., Xiao, Y., Decker, P. A., Ballman, K. V., Berger, M., Buckner, J. C., Chang, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.408 · Cited by 510
Mirimanoff, R.-O., Gorlia, T., Mason, W., Van den Bent, M. J., Kortmann, R.-D., Fisher, B., Reni, M., Brandes, A. A., Curschmann, J., Villa, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5963 · Cited by 509
Self-citationCellular-Telephone Use and Brain Tumors
Inskip, P. D., Tarone, R. E., Hatch, E. E., Wilcosky, T. C., Shapiro, W. R., Selker, R. G., Fine, H. A., Black, P. M., Loeffler, J. S., & Linet, M. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101113440201 · Cited by 483
Monoclonal antibody specific for IDH1 R132H mutation
Capper, D., Zentgraf, H., Balss, J., Hartmann, C., & von Deimling, A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0595-z · Cited by 436
Ay, C., Vormittag, R., Dunkler, D., Simanek, R., Chiriac, A.-L., Drach, J., Quehenberger, P., Wagner, O., Zielinski, C., & Pabinger, I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7752 · Cited by 422
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Ryken, T. C., McDermott, M., Robinson, P. D., Ammirati, M., Andrews, D. W., Asher, A. L., Burri, S. H., Cobbs, C. S., Gaspar, L. E., Kondziolka, D., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0057-4 · Cited by 363
Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
Chang, S. M. (2005) · JAMA · doi:10.1001/jama.293.5.557 · Cited by 362
Genetic alterations and signaling pathways in the evolution of gliomas
Ohgaki, H., & Kleihues, P. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01308.x · Cited by 355
Health-related quality of life in patients with glioblastoma: a randomised controlled trial
Taphoorn, M. J., Stupp, R., Coens, C., Osoba, D., Kortmann, R., van den Bent, M. J., Mason, W., Mirimanoff, R. O., Baumert, B. G., Eisenhauer, E., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70432-0 · Cited by 331
Self-citationThe management of brain edema in brain tumors
Kaal, E. C. A., & Vecht, C. J. (2004) · Current Opinion in Oncology · doi:10.1097/01.cco.0000142076.52721.b3 · Cited by 292
Sampson, J. H., Archer, G. E., Mitchell, D. A., Heimberger, A. B., Herndon, J. E., Lally-Goss, D., McGehee-Norman, S., Paolino, A., Reardon, D. A., Friedman, A. H., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0124 · Cited by 287
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma
Semrad, T. J., O'Donnell, R., Wun, T., Chew, H., Harvey, D., Zhou, H., & White, R. H. (2007) · Journal of Neurosurgery · doi:10.3171/jns.2007.106.4.601 · Cited by 284
Seizure Prophylaxis in Patients With Brain Tumors: A Meta-analysis
Sirven, J. I., Wingerchuk, D. M., Drazkowski, J. F., Lyons, M., & Zimmerman, R. S. (2004) · Mayo Clinic Proceedings · doi:10.4065/79.12.1489 · Cited by 276
Marras, L. C., Geerts, W. H., & Perry, J. R. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3<640::aid-cncr20>3.0.co;2-e · Cited by 273
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., Schultz, L., & Mikkelsen, T. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9718-y · Cited by 272
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Self-citationTemozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
Brada, M., Stenning, S., Gabe, R., Thompson, L. C., Levy, D., Rampling, R., Erridge, S., Saran, F., Gattamaneni, R., Hopkins, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.1932 · Cited by 249
Self-citationRaymond, E., Brandes, A. A., Dittrich, C., Fumoleau, P., Coudert, B., Clement, P. M. J., Frenay, M., Rampling, R., Stupp, R., Kros, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9235 · Cited by 227
Self-citationRadiographic patterns of relapse in glioblastoma
Chamberlain, M. C. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0251-4 · Cited by 215
Reardon, D. A., Nabors, L. B., Stupp, R., & Mikkelsen, T. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1225 · Cited by 206
Self-citationOperative Techniques for Gliomas and the Value of Extent of Resection
Sanai, N., & Berger, M. S. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.005 · Cited by 196
Mobile phone use and risk of glioma in 5 North European countries
Lahkola, A., Auvinen, A., Raitanen, J., Schoemaker, M. J., Christensen, H. C., Feychting, M., Johansen, C., Klæboe, L., Lönn, S., Swerdlow, A. J., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22503 · Cited by 192
Medical management of patients with brain tumors
Wen, P. Y., Schiff, D., Kesari, S., Drappatz, J., Gigas, D. C., & Doherty, L. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9193-2 · Cited by 191
Wöhrer, A., Waldhör, T., Heinzl, H., Hackl, M., Feichtinger, J., Gruber-Mösenbacher, U., Kiefer, A., Maier, H., Motz, R., Reiner-Concin, A., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9938-9 · Cited by 189
Self-citationPsychosocial and supportive-care needs in high-grade glioma
Catt, S., Chalmers, A., & Fallowfield, L. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70230-4 · Cited by 183
Antiepileptic drugs for preventing seizures in people with brain tumors
Tremont-Lukats, I. W., Ratilal, B. O., Armstrong, T., & Gilbert, M. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004424.pub2 · Cited by 172
Grossman, S. A., Ye, X., Chamberlain, M., Mikkelsen, T., Batchelor, T., Desideri, S., Piantadosi, S., Fisher, J., & Fine, H. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6895 · Cited by 172
End of life issues in brain tumor patients
Pace, A., Lorenzo, C. D., Guariglia, L., Jandolo, B., Carapella, C. M., & Pompili, A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9670-x · Cited by 159
Dresemann, G. P., Weller, M., Rosenthal, M. A., Wedding, U., Wagner, W., Engel, E., Heinrich, B., Mayer‐Steinacker, R., Krarup‐Hansen, A., Fluge, Ø., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9976-3 · Cited by 156
Self-citationManagement of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors
Gerber, D. E., Grossman, S. A., & Streiff, M. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6656 · Cited by 150
Raijmakers, N. J. H., van Zuylen, L., Costantini, M., Caraceni, A. T., Clark, J. B., Lundquist, G., Voltz, R., Ellershaw, J., & van der Heide, A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq620 · Cited by 147
Reardon, D. A., Dresemann, G. P., Taillibert, S., Campone, M., van den Bent, M. J., Clément, P. M., Blomquist, E., Gordower, L., Schultz, H., Raizer, J. J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605411 · Cited by 141
Li, L., Quang, T. S., Gracely, E., Kim, J. H., Emrich, J., Yaeger, T. E., Jenrette, J. M., Cohen, S. C., Black, P., & Brady, L. W. (2010) · Journal of neurosurgery · doi:10.3171/2010.2.jns091211 · Cited by 139
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
Pope, W. B., Xia, Q., Paton, V. E., Das, A., Hambleton, J., Kim, H. J., Huo, J., Brown, M. S., Goldin, J. G., & Cloughesy, T. F. (2011) · Neurology · doi:10.1212/wnl.0b013e31820a0a8a · Cited by 120
Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis
Jos, M. A. K., Onno, P. M. T., Alphons, G. H. K., Marcel, J. H. M. H., & Emiel, A. M. B. (1996) · Seizure · doi:10.1016/s1059-1311(96)80023-9 · Cited by 113
Butowski, N. A., Chang, S. M., Junck, L., DeAngelis, L. M., Abrey, L. E., Fink, K., Cloughesy, T. F., Lamborn, K. R., Salazar, A. Μ., & Prados, M. D. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9693-3 · Cited by 112
Rechallenge with temozolomide in patients with recurrent gliomas
Wick, A., Pascher, C., Wick, W., Jauch, T., Weller, M., Bogdahn, U., & Hau, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5006-9 · Cited by 108
Self-citationAntiepileptic Drug Monotherapy: The Initial Approach in Epilepsy Management
Louis, E. K. S., Rosenfeld, W. E., & Bramley, T. J. (2009) · Current Neuropharmacology · doi:10.2174/157015909788848866 · Cited by 106
Sabel, M., & Giese, A. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802508180 · Cited by 95
Epilepsy in cerebral glioma: timing of appearance and histological correlations
Rosati, A., Tomassini, A., Pollo, B., Ambrosi, C., Schwarz, A., Padovani, A., & Bonetti, B. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9796-5 · Cited by 87
Bevacizumab does not increase the risk of remote relapse in malignant glioma
Wick, A., Dörner, N., Schäfer, N., Höfer, S., Heiland, S., Schemmer, D., Platten, M., Weller, M., Bendszus, M., & Wick, W. (2010) · Annals of Neurology · doi:10.1002/ana.22336 · Cited by 84
Self-citationIntegrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme
Veeravagu, A., Liu, Z., Niu, G., Chen, K., Jia, B., Cai, W., Jin, C., Hsu, A. R., Connolly, A. J., Tse, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0797 · Cited by 80
Riva, M. A., Salmaggi, A., Marchioni, E., Silvani, A., Tomei, G., Lorusso, L., Merli, R., Imbesi, F., Russo, A., & for the Lombardia Neurooncology Group (2006) · Neurological Sciences · doi:10.1007/s10072-006-0708-6 · Cited by 42
Perry, J., Rogers, L., Laperrière, N., Julian, J. A., Geerts, W. H., Agnelli, G., Malkin, M. G., Sawaya, R., Baker, R. I., & Levine, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2011 · Cited by 42
Signaling in Malignant Astrocytomas: Role of Neural Stem Cells and Its Therapeutic Implications
Llaguno, S. R. A., Chen, J., & Parada, L. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0433 · Cited by 40
New molecular targets in malignant gliomas
de Groot, J., & Gilbert, M. R. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f15650 · Cited by 39
Molecularly targeted therapies for glioma
Yamanaka, R., & Saya, H. (2009) · Annals of Neurology · doi:10.1002/ana.21793 · Cited by 35
Stupp, R., Kanner, A. A., Engelhard, H. H., Heidecke, V., Taillibert, S., Lieberman, F. S., Dbalý, V., Kirson, E. D., Palti, Y., & Gutin, P. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.18_suppl.lba2007 · Cited by 24
Self-citation
Cited by
High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stupp, R., Brada, M., van den Bent, M. J., Tonn, J.-C., & Pentheroudakis, G. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu050 · Cited by 772
Self-citationStandards of care for treatment of recurrent glioblastoma—are we there yet?
Weller, M., Cloughesy, T., Perry, J. R., & Wick, W. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 771
Self-citationNanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Berghoff, A. S., Kiesel, B., Widhalm, G., Rajky, O., Ricken, G., Wöhrer, A., Dieckmann, K., Filipits, M., Brandstetter, A., Weller, M., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou307 · Cited by 585
Self-citationXin, H., Sha, X., Jiang, X., Zhang, W., Chen, L., & Fang, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.046 · Cited by 311
Metadata
- Authors
- Preusser, M., de Ribaupierre, S., Wöhrer, A., Erridge, S. C., Hegi, M., Weller, M., & Stupp, R.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 70
- Issue
- 1
- Pages
- 9-21
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2164049072
- Cited by
- 461
- References
- 86
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.